Table 1. Comparison of characteristics of patients diagnosed with prostate cancer between 2006 and 2015.
| Characteristics | Total | 2006–2010 | 2011–2015 | P | |
|---|---|---|---|---|---|
| No. of patients | 675 (100.0) | 224 (33.2) | 451 (66.8) | ||
| Age, yr | 68.7 (62.8–74.2) | 67.8 (61.3–73.4) | 69.3 (63.2–74.5) | 0.672 | |
| PSA, ng/mL | 9.09 (5.62–25.06) | 9.13 (5.44–29.11) | 8.98 (5.71–23.30) | 0.319 | |
| Gleason score | 0.140 | ||||
| 6 | 218 (32.3) | 79 (35.3) | 139 (30.8) | ||
| 7 | 180 (26.7) | 65 (29.0) | 115 (25.5) | ||
| 8–10 | 277 (41.0) | 80 (35.7) | 197 (43.7) | ||
| NCCN risk stratification | 0.001 | ||||
| Very low | 20 (3.0) | 4 (1.8) | 16 (3.5) | ||
| Low | 77 (11.4) | 12 (5.4) | 65 (14.4) | ||
| Intermediate | 202 (29.9) | 83 (37.1) | 119 (26.4) | ||
| High | 132 (19.6) | 36 (16.1) | 96 (21.3) | ||
| Very high | 110 (16.3) | 37 (16.5) | 73 (16.2) | ||
| Regional | 37 (5.5) | 12 (5.4) | 25 (5.5) | ||
| Metastatic | 97 (14.4) | 40 (17.9) | 57 (12.6) | ||
| SEER summary stage | 0.189 | ||||
| Localized | 398 (59.0) | 126 (56.3) | 272 (60.3) | ||
| Regional | 180 (26.7) | 46 (20.5) | 97 (21.5) | ||
| Distant | 97 (14.3) | 52 (23.2) | 82 (18.2) | ||
| CAPRA scores | 474 (70.2) | 152 (67.9) | 322 (71.4) | 0.663 | |
| 0–2 | 159 (33.5) | 55 (36.2) | 104 (32.2) | ||
| 3–5 | 187 (39.5) | 59 (38.8) | 128 (39.8) | ||
| 6–10 | 128 (27.0) | 38 (25.0) | 90 (28.0) | ||
| Initial treatment | 0.002 | ||||
| AS | 9 (1.3) | 2 (0.9) | 7 (1.6) | ||
| RP | 285 (42.2) | 114 (50.9) | 171 (37.9) | ||
| RT + ADT | 257 (38.1) | 64 (28.6) | 193 (42.8) | ||
| ADT | 124 (18.4) | 44 (19.6) | 80 (17.7) | ||
Data are presented as number (%) or median (interquartile range).
PSA = prostate-specific antigen, NCCN = National Comprehensive Cancer Network, SEER = Surveillance, Epidemiology, and End Results, CAPRA = Cancer of the Prostate Risk Assessment, AS = active surveillance, RP = radical prostatectomy, RT = radiotherapy, ADT = androgen deprivation therapy.